GlassScriptPhysician profile
John C Galanis
NPI 1215921069
$19,724.14
in general payments reported to CMS, 2019-2025
32 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,458 · 2020: $5,504 · 2021: $1,550 · 2022: $1,590 · 2023: $1,907 · 2024: $1,432 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,621.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,926.53 | 2019-2022 | |
| Abbvie INC. | $1,826.35 | 2022-2025 | |
| Alcon Vision LLC | $1,362.78 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $690.88 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $687.88 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $436.76 | 2019-2024 | Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $430.44 | 2019-2021 | |
| New World Medical,INC. | $351.60 | 2021-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Sun Pharmaceutical Industries INC. | $276.71 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $213.43 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $212.30 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $201.47 | 2023 | Quatera 700, Lumera 700 |
| Sight Sciences, INC. | $199.15 | 2021-2025 | Omni Surgical System |
| Oyster Point Pharma, INC. | $189.25 | 2022-2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $187.95 | 2023-2024 | Acthar |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $185.06 | 2019-2023 | |
| Thea Pharma INC. | $173.47 | 2022-2025 | Iyuzeh |
| Glaukos Corporation | $150.56 | 2022-2023 | |
| Nova Eye, INC. | $142.82 | 2023 | |
| Rxsight INC | $136.99 | 2022-2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Ocular Therapeutix, INC. | $109.81 | 2021-2025 | Dextenza |
| Ivantis, INC | $107.71 | 2019-2020 | |
| Eyepoint US, INC. | $99.10 | 2019 | |
| Eyevance Pharmaceuticals LLC | $95.22 | 2019-2022 | |
| Biotissue Holdings INC. | $86.56 | 2019-2020 | |
| Harrow Eye, LLC | $62.31 | 2023-2024 | Iheezo |
| Astellas Pharma US INC | $56.18 | 2023-2025 | Izervay |
| Lumenis, INC | $35.33 | 2021 | |
| Shire North American Group INC | $28.96 | 2019 | |
| Horizon Therapeutics Plc | $22.31 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $18.87 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Galanis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.